Genotypes and MAF of CD148 polymorphisms in control subjects and HIT patients
| . | Abneg (n = 179) . | Abpos (n = 160) . | HIT (n = 97) . | OR (95% CI) . | P* . |
|---|---|---|---|---|---|
| Q276P (rs1566734) | |||||
| Genotypes n (%) | |||||
| 116 (65) | 113 (70.5) | 81 (83.5) | 0.36 (0.20-0.67)* | .001* | |
| QP + PP† | 63 (35) | 47 (29.5) | 16 (16.5) | 0.47 (0.25-0.89)** | .03** |
| MAF | |||||
| P | 0.19 | 0.16 | 0.09 | 0.41 (0.23-0.73)* | .003* |
| 0.52 (0.29-0.94)** | .03** | ||||
| R326Q (rs1503185) | |||||
| Genotypes n (%) | |||||
| RR | 114 (63.5) | 112 (70) | 80 (82.5) | 0.37 (0.20-0.68)* | .002* |
| RQ + QQ† | 65 (36.5) | 48 (30) | 17 (17.5) | 0.50 (0.27-0.92)** | .04** |
| MAF | |||||
| Q | 0.205 | 0.16 | 0.10 | NS | |
| D872E (rs4752904) | |||||
| Genotypes n (%) | |||||
| DD | 58 (32.5) | 59 (37) | 39 (40.2) | NS | |
| DE | 97 (54) | 83 (51) | 39 (40.2) | ||
| EE | 24 (13.5) | 18 (11) | 19 (19.5) | ||
| MAF | |||||
| E | 0.405 | 0.37 | 0.395 | NS |
| . | Abneg (n = 179) . | Abpos (n = 160) . | HIT (n = 97) . | OR (95% CI) . | P* . |
|---|---|---|---|---|---|
| Q276P (rs1566734) | |||||
| Genotypes n (%) | |||||
| 116 (65) | 113 (70.5) | 81 (83.5) | 0.36 (0.20-0.67)* | .001* | |
| QP + PP† | 63 (35) | 47 (29.5) | 16 (16.5) | 0.47 (0.25-0.89)** | .03** |
| MAF | |||||
| P | 0.19 | 0.16 | 0.09 | 0.41 (0.23-0.73)* | .003* |
| 0.52 (0.29-0.94)** | .03** | ||||
| R326Q (rs1503185) | |||||
| Genotypes n (%) | |||||
| RR | 114 (63.5) | 112 (70) | 80 (82.5) | 0.37 (0.20-0.68)* | .002* |
| RQ + QQ† | 65 (36.5) | 48 (30) | 17 (17.5) | 0.50 (0.27-0.92)** | .04** |
| MAF | |||||
| Q | 0.205 | 0.16 | 0.10 | NS | |
| D872E (rs4752904) | |||||
| Genotypes n (%) | |||||
| DD | 58 (32.5) | 59 (37) | 39 (40.2) | NS | |
| DE | 97 (54) | 83 (51) | 39 (40.2) | ||
| EE | 24 (13.5) | 18 (11) | 19 (19.5) | ||
| MAF | |||||
| E | 0.405 | 0.37 | 0.395 | NS |
MAF indicates minor allele frequency.
P values and ORs were calculated for genotype and allele frequencies between *Abneg and HIT and **Abpos and HIT.
Only few patients were homozygous 276PP or 326QQ. Therefore, we compared carriers of the 276P or 326Q allele (heterozygous + homozygous) to nonmutated subjects.